Clemastine Fumarate is a first-generation ethanolamine H1-receptor antagonist with marked sedative properties, used for allergic rhinitis and urticaria, and increasingly studied for remyelination potential in multiple sclerosis research. Simson Pharma's Clemastine Fumarate reference standard and impurities support compendial testing across these applications.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Clemastine Fumarate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.